通用汽車:晶片短缺或下半年有改善 尋求與晶片商建立合作夥伴關係
通用汽車(GM.US)財務總監Paul Jacobson表示,正考慮未來與晶片及晶圓供應商合作,又或者簽署長期供應合約,以減輕對全球半導體短缺的影響。
通用汽車曾表示,晶片短缺可能會令今年的利潤減少15至20億美元,不過最近一些被逼停工的工廠重新開始生產。
Jacobson稱,雖然預計下半年晶片短缺情況會有所改善,但馬來西亞疫情爆發等問題仍在影響晶片行業,若情況繼續下去,一些主要晶片供應商將未能向公司供貨,目前公司已經採用空運來運送晶片。
Jacobson提到,市場對汽車的需求依然強勁,預計情況至少會持續到第四季,如果需求仍然高企而晶片供應依然不足,汽車庫存緊張的情況將持續到明年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.